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Summary
Phosphoinositide 3-kinase (PI3K) type IA is a heterodimer of a catalytic subunit, p110, and a regulatory subunit, p85. Here
we show that p85 contains a GTPase-responsive domain and an inhibitory domain, which together form a molecular switch
that regulates PI3K. H-Ras and Rac1 activate PI3K by targeting the GTPase-responsive domain. The stimulatory effect of
these molecules, however, is blocked by the inhibitory domain, which functions by binding to tyrosine-phosphorylated
molecules and is neutralized by tyrosine phosphorylation. The complementary effects of tyrosine kinases and small GTPases
on the p85 molecular switch result in synergy between these two classes of molecules toward the activation of the PI3K/
Akt pathway.
Introduction with direct binding between Ras and p110 (Rodriguez-Viciana
et al., 1994), while PI3K activation by Rac1 may be mediated
by binding of Rac1 to p85 (Tolias et al., 1995; Zheng et al.,Phosphoinositide 3-kinase (PI3K) type IA, a heterodimer of a
regulatory subunit (p85) and a catalytic subunit (p110), catalyzes 1994). However, we and others have recently found that direct
interaction of PI3K with either H-Ras or Rac1 is not requiredthe phosphorylation of PtdIns-4,5-P2 to form PtdIns-3,4,5-P3
(Wymann and Pirola, 1998). PtdIns-3,4,5-P3, in turn, regulates for PI3K activation (Karasarides et al., 2001; see Supplemental
Figure S1 at http://www.cancercell.org/cgi/content/full/1/2/a diverse array of cellular functions including apoptosis, prolifer-
ation, differentiation, and intermediary metabolism (Chan et al., 181/DC1). Moreover, constitutively active Ras activates the
PI3K/Akt pathway in synergy with Src (Datta et al., 1996), sug-1999; Rameh and Cantley, 1999). PI3K is activated rapidly fol-
lowing growth factor stimulation and crosslinking of cell adhe- gesting that signals transduced via small GTPases and tyrosine
kinases regulate this pathway cooperatively.sion molecules (Rameh and Cantley, 1999). Despite extensive
studies on the mechanism of PI3K activation by these signals, The studies in this manuscript reexamine the role of tyrosine
kinases and small GTPases in PI3K activation in vivo. The reasonhowever, significant questions remain unanswered.
Earlier studies suggested that the binding of the regulatory we focus on the regulation of PI3K in vivo is that critical factors
involved in its regulation are lost upon purification. Thus, in thesubunit of PI3K to tyrosine-phosphorylated molecules is directly
responsible for PI3K activation (Backer et al., 1992; Carpenter absence of growth factor or integrin stimulation, PI3K fails to
catalyze PtdIns-3,4,5-P3 synthesis in vivo (Wymann and Pirola,et al., 1993). However, recent in vitro studies (Layton et al.,
1998) and earlier in vivo studies (Fukui and Hanafusa, 1989; 1998). However, the enzyme becomes constitutively active upon
purification. Moreover, Carpenter et al. found that higher PI3K-Varticovski et al., 1991) suggested that binding is not sufficient
to activate PI3K. Other studies showed that PI3K is also acti- specific activity in vitro correlates with increasing purity of PI3K
preparations (Carpenter et al., 1990). Finally, PI3K immunopuri-vated by small GTPase molecules such as Ras and Rac1 (Ni-
shida et al., 1999; Rodriguez-Viciana et al., 1994). These mole- fied from serum-starved cells has the same specific activity as
PI3K from PDGF-stimulated cells (Hu et al., 1992). These studiescules activate PI3K by diverse, although not clearly defined,
mechanisms. Thus, PI3K activation by Ras has been correlated indicate that inhibitory factors, lost upon purification, block PI3K
S I G N I F I C A N C E
Upon stimulation by many extracellular stimuli, PI3K type IA catalyzes the synthesis of phosphatidylinositol-3,4,5-P3, a second messen-
ger that regulates cell growth, proliferation, apoptosis, and intermediary metabolism. Interestingly, the cellular levels of phosphatidyl-
inositol-3,4,5-P3 are elevated in almost all cancers through the acquisition of mutations in tyrosine kinases, small GTPases, and the
phosphatidylinositol-3 phosphatase, PTEN. Data in this report suggest a unifying model of PI3K activation by tyrosine kinases and
small GTPases, according to which these two classes of signaling molecules act in concert to trigger a molecular switch that regulates
PI3K. Given the importance of phosphatidylinositol-3,4,5-P3 and its target Akt, in human cancer, the molecular switch described in
this paper defines an important target for future chemotherapeutic drugs.
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activity in vivo (Carpenter et al., 1990). Though phosphotyrosine
peptides have been shown to modestly enhance type IA PI3K
activity in vitro (Backer et al., 1992; Carpenter et al., 1993),
Layton et al. showed, and we confirmed, that this enhancement
depends on conditions used for the in vitro assay (Layton et
al., 1998; see Supplemental Figure S2 at http://www.cancercell.
org/cgi/content/full/1/2/181/DC1) and that phosphotyrosine
binding alone is not sufficient to activate PI3K in vivo. Based
on the results of the studies described in this report, we propose
a unifying model according to which all tyrosine kinases and
small GTPases activate PI3K by acting synergistically on a mo-
lecular switch in p85.
Results
Wild-type p85 and carboxy-terminally truncated p85
exert opposite effects on PtdIns-3,4,5-P3 synthesis
induced by H-Ras or Rac1
Earlier studies had shown that a truncated p85 molecule lacking
the carboxy-terminal SH2 domain and 52 adjacent amino acids
from the inter-SH2 (iSH2) region, referred to as p85onc in this
communication, activates PI3K constitutively and transforms
cells in culture (Jimenez et al., 1998). Wild-type p85, on the
other hand, blocks H-Ras-induced PI3K activation and cellular
transformation (Rodriguez-Viciana et al., 1997). This raised the
question whether p85onc and p85 differ in their ability to regu-
late PI3K activation by H-Ras. To address this question, we
used a thin-layer chromatography-based assay (Maehama and
Dixon, 1998) to separate PtdIns-3,4,5-P3 from lipid extracts of
32P-labeled NIH3T3 cells transfected with Hemagglutinin (HA)-
tagged constructs of wild-type p85 (HA-p85-WT) or p85onc
(HA-p85onc) and constitutively-active H-Ras (H-Ras G12V) in
the combinations shown in Figure 1B. HA-p85-WT and HA-
Figure 1. p85 inhibits while p85onc enhances PI3K activation by small
p85onc were both expressed at similar levels (Figure 1A). Con- GTPases
sistent with the findings of Jimenez et al. (1998), HA-p85onc A: Schematic diagrams and expression of transiently transfected HA-
alone weakly activated PI3K in vivo (Figure 1B, upper gel). p85 tagged p85-WT and p85onc constructs. B: Top: p85-WT inhibits while
p85onc enhances H-Ras-induced PtdIns-3,4,5-P3 production. The indi-and p85onc, however, had diametrically opposite effects when
cated constructs were transiently transfected into NIH3T3 cells. Sixteen hourscotransfected with Ras in that whereas p85 inhibited the activa-
after transfection, the cells were cultured in serum-free media. Five hourstion of PI3K, p85onc enhanced it dramatically. Figure 1C
later, they were labeled with 32P-orthophosphate for 1.5 hr. Total phospholip-
shows that the synergy between H-Ras and p85onc is wort- ids were analyzed by thin-layer chromatography. Bottom: p85-WT inhibits
mannin sensitive, and therefore, PI3K dependent. while p85onc enhances H-Ras-induced Akt phosphorylation. Immunoblots
of cell extracts from duplicate transfections were probed with an antibodyPtdIns-3,4,5-P3 synthesized by the activated PI3K is re-
that recognizes Akt phosphorylated at Thr308 or with antibodies that recog-quired for activation of the Akt kinase (Chan et al., 1999). This
nize the proteins expressed from the transfected constructs. C: PtdIns-suggests that Akt phosphorylation and activity may correlate 3,4,5-P3 induction by p85onc and constitutively active H-Ras is inhibited
with the intracellular levels of PtdIns-3,4,5-P3. To address this by the PI3K inhibitor, wortmannin. NIH3T3 cells were transiently transfected
with the indicated constructs, and they were labeled with 32P-orthophos-question, we probed an immunoblot of cell lysates derived from
phate as described in B. 45 minutes prior to lipid extraction, the cells werethe cells in the preceding experiment, with an antibody that
treated with 100 nM wortmannin or DMSO. D: p85onc synergizes with Rac1recognizes the phosphorylated Thr308 motif of Akt. The results
to induce PtdIns-3,4,5-P3 synthesis and Akt activation. NIH3T3 cells were(Figure 1B, lower gel) confirmed the predicted correlation be- transiently transfected with the indicated constructs. 32P-labeled PtdIns-
tween Akt phosphorylation and PtdIns-3,4,5-P3 levels. The fact 3,4,5-P3 was measured as described in B. Akt phosphorylation at Thr308 and
expression of transfected constructs were determined by probing immu-that Ras and p85onc activate Akt via PI3K and not via direct
noblots with the corresponding antibodies.phosphorylation of Akt was further confirmed by experiments
showing that the combination of Ras and p85onc does not
activate Akt in PDK1/ cells (see Supplemental Figure S3 at
http://www.cancercell.org/cgi/content/full/1/2/181/DC1). that the levels of PtdIns-3,4,5-P3 correlate with the phosphoryla-
We next examined whether p85onc synergizes with small tion of Akt at Thr308. Based on these observations, we decided
GTPases other than Ras to activate the PI3K pathway. Figure to use the in vitro kinase activity of Akt to monitor the in vivo
1D (upper gel) shows that the combination of transiently trans- activity of PI3K. The results of critical experiments were con-
fected, constitutively active Rac1 (Rac1 Q61L) and p85onc in firmed by direct measurement of the intracellular levels of
NIH3T3 cells dramatically enhanced the intracellular levels of PtdIns-3,4,5-P3.
PI3K activation via the synergistic actions of Rac1 andPtdIns-3,4,5-P3. The lower gel of the same figure shows again
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Figure 2. Membrane-targeted p85 continues to
block PI3K/Akt activation by H-Ras
A: Schematic diagrams of HA-tagged Myrp85-
WT and Myrp85onc. NIH3T3 cells transfected
with these constructs were fixed with paraformal-
dehyde, and they were incubated with the anti-
HA antibody. Bound antibody was visualized by
fluorescein isothiocyanate (FITC)-labeled goat
anti-mouse antiserum and fluorescence confo-
cal microscopy. B: Myrp85-WT inhibits PI3K acti-
vation by H-Ras. Constitutively active H-Ras and
FLAG-c-Akt were transfected into NIH3T3 cells in
combination with Myrp85-WT or vector. The in
vitro phosphorylation of Histone 2B (H2B) by
FLAG-Akt immunoprecipitates was measured by
phosphorimager. Akt levels in the immunopre-
cipitates were measured by immunoblotting and
laser densitometry scanning (Molecular Dynam-
ics). The bar graphs show the specific activity of
Akt as calculated from these two values. H2B
phosphorylation is presented in arbitrary units. C:
Myrp85onc enhances PI3K activation by H-Ras.
Constitutively active H-Ras was transfected in
combination with Myrp85onc or vector into
NIH3T3 cells. The specific activity of Akt was de-
termined as in B.
p85onc does not depend on the binding of Rac1 to p110, In vitro kinase assays of FLAG-Akt revealed that membrane-
targeted p85 is similar to the wild-type protein in that it doesbecause these proteins do not interact (Tolias et al., 1995; Zheng
et al., 1994). Therefore, if Rac1 and H-Ras synergize with not activate the PI3K/Akt pathway by itself and in that it blocks
activation of the pathway by H-Ras (Figure 2B). Myrp85onc,p85onc via similar mechanisms, the synergy of H-Ras with
p85onc should also be independent of the interaction between on the other hand, was similar to p85onc in that it activated
the PI3K/Akt pathway both alone and in synergy with H-RasH-Ras and p110. Recent studies by us and others revealed that
this is indeed the case. Karasarides et al. (2001) recently showed (Figure 2C). We conclude that association of p85 with the plasma
membrane is not sufficient to activate PI3K. Therefore, the car-that an activated H-Ras mutant (Y64G/Y71G/F156L), which fails
to bind p110, activates the PI3K/Akt pathway in vivo. Similarly, boxy-terminal truncation of p85 is unlikely to activate PI3K by
targeting the enzyme to the plasma membrane. A more likelywe found that both H-Ras G12V/E37G and H-Ras G12V/Y40C,
two activated H-Ras mutants of which only the latter interacts possibility is that truncation unveils a domain in p85 that re-
sponds to Ras- or Rac1-transduced signals to activate PI3Kwith p110 (Rodriguez-Viciana et al., 1997; White et al., 1995),
synergize equally well with p85onc to activate PI3K (see Sup- (GTPase-responsive domain, GRD). Subsequent experiments
were designed to map the GRD within p85.plemental Figure S1 at http://www.cancercell.org/cgi/content/
full/1/2/181/DC1). The same figure shows that overexpression
of the BCR domain of p85, which is known to bind Rac1 (Tolias A protein motif within the iSH2 domain of p85
synergizes with H-Ras and Rac1 to activateet al., 1995; Zheng et al., 1994), does not inhibit PI3K activation
by Rac1. Therefore, the Rac1/p85 interaction is also not required the PI3K/Akt pathway
The p85 regulatory subunit of PI3K contains several proteinfor PI3K activation.
domains, including SH3, BCR homology, two SH2 domains,
and an inter-SH2 domain (iSH2; Figure 3A). Computer modelingMembrane localization of p85 is not sufficient
to activate PI3K of the iSH2 domain suggested that this region resembles a
coiled-coil structure (Wymann and Pirola, 1998). A motif (TIF),Truncated p85 is thought to activate PI3K by directing it to the
plasma membrane (Jimenez et al., 1998). We, therefore, tested previously mapped within this structure, binds the PI3K catalytic
subunit, p110 (Dhand et al., 1994). The TIF motif is highly con-whether membrane-associated full-length p85 is functionally
similar to the carboxy-terminally truncated protein. To this end, served across p85 subtypes (, , and ) and across species
(bovine, rat, and Drosophila; Figure 3A). Other conserved motifsp85 fused at its amino terminus to a peptide encoding the Src
myristoylation signal (Myrp85-WT; Figure 2A) was transiently include a motif we named IKR, which is rich in isoleucine, lysine,
and arginine residues, and a motif we named LED, which is richexpressed in NIH3T3 cells in combination with FLAG-Akt or
FLAG-Akt plus H-Ras. Myrp85onc was used as a control. The in leucine, glutamic acid, and aspartic acid residues. The LED
motif is located downstream from the IKR motif and correspondscells were lysed 48 hr later, following overnight serum starvation.
Akt activation in this and subsequent experiments was deter- to the carboxyl terminus of the iSH2 domain. The carboxyl
terminus of the IKR motif corresponds to the breakpoint of themined by measuring the phosphorylation of histone 2B (H2B)
by immunoprecipitated Akt. p85 oncogenic truncation.
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Figure 3. The carboxy-terminally truncated inter-
SH2 domain of p85 synergizes with Ras and Rac1
to activate the PI3K/Akt pathway.
A: Schematic diagram of wild-type p85 and se-
quence comparison of inter-SH2 domains. Line-
up of the amino acid sequence of several p85
iSH2 domains, bovine p85-(M61745), Rat p85-
(NM_022185), bovine p85- (AF036256), and Dro-
sophila p85(Y11143). Conserved amino acid mo-
tifs include TIF (p110 binding motif), IKR, and LED.
B: The p85-iSH2 domain lacking 52 amino acids
from its carboxyl terminus synergizes with both
activated H-Ras and activated Rac1. (Left)
Schematic diagram shows an HA-tagged con-
struct of the inter-SH2 domain carrying the same
carboxy-terminal truncation as p85onc (p85-
iSH2onc). (Right) The indicated constructs were
transiently transfected into NIH3T3 cells. Akt ac-
tivity was measured by in vitro phosphorylation
of H2B. Expression of proteins encoded by the
transfected constructs was determined by prob-
ing immunoblots of total lysates with the anti-
HA antibody. C: The p85 IKR motif is a required
component of the GRD domain. Schematic dia-
gram on the left shows the domain composition
of transfected constructs. These constructs were
transfected into NIH3T3 cells together with an
expression construct of constitutively active
H-Ras. Akt activity was measured by Akt phos-
phorylation at Thr308. Expression of the trans-
fected constructs were determined by probing
immunoblots with the corresponding antibodies.
Given that the p85 oncogenic truncation separates the TIF phorylated Thr308 motif of Akt revealed that the deletion of IKR
abolishes iSH2onc function (Figure 3C). We conclude that theand IKR motifs from the LED motif, we examined whether the
IKR motif is a required component of the GRD domain.TIF/IKR portion of iSH2 (p85-iSH2onc; Figure 3A) synergizes
with Ras or Rac1 to activate the PI3K pathway. To this end,
we transfected NIH3T3 cells with FLAG-Akt and activated H-Ras The LED and cSH2 motifs of p85 define a modular
inhibitory domainG12V or activated Rac1 Q61L in combination with p85-iSH2onc.
The Akt kinase activity was measured 48 hr later, following The blockage of Ras signal by wild-type p85, but not by
p85onc, suggests that the carboxy-terminal region of this mol-serum starvation for 16 hr. The results showed that iSH2onc,
indeed, activates the PI3K/Akt pathway, alone and in synergy ecule may contain an inhibitory domain. To test this hypothesis,
we transfected NIH3T3 cells with H-Ras G12V in combinationwith H-Ras or Rac1 (Figure 3B). However, iSH2onc did not
bind either Ras or Rac1 (data not shown), suggesting that the with expression constructs of the carboxyl terminus of p85 (p85-
CT, amino acids 514–725) or p85-DN, a known dominant-nega-functional interaction between iSH2onc and these molecules
is likely to be indirect. Next, we examined whether the IKR motif tive mutant of p85 (deletion of amino acids 479–513) (Dhand
et al., 1994). After overnight serum starvation, the activity ofis necessary for iSH2onc function. To this end, the intact nSH2/
iSH2onc and nSH2/ iSH2onc molecules with carboxy-termi- cotransfected FLAG-Akt was examined. The results showed
that p85-CT is as efficient as p85-DN at inhibiting the Ras signalnal deletions of the IKR or the IKR plus TIF motifs were fused
to Hemagglutinin-tagged green fluorescence protein (HA-GFP). (Figure 4B) and confirmed that the carboxyl terminus of p85
contains a modular inhibitory domain.The GFP fusion constructs were transiently transfected in com-
bination with FLAG-Akt into NIH3T3 cells. Probing an immu- To map the p85-CT motifs required for the inhibitory func-
tion, we fused p85-CT or portions of it with HA-GFP (Figurenoblot of cell lysates with an antibody that recognizes the phos-
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Figure 5. The PI3K inhibitory domain inhibits p110, but not p110
The inhibition is independent of PTEN. A and B: p85-CT and p85-DN block
Akt activation by constitutively active p110-CAAX. NIH3T3 cells were trans-
fected with the indicated constructs. Akt activity was measured by in vitro
phosphorylation of H2B. C: p85-CT and p85-DN block Akt activation by Ras
in the absence of PTEN. The PTEN null (Li et al., 1997) human glioblastoma
cell line, U87MG, was transfected with the indicated constructs. Phosphory-
lation of Akt at Thr308 was measured in lysates of the transfected cells by
immunoblotting.
The p85 inhibitory domain targets PI3K
type IA and not PTEN
Figure 4. The carboxy-terminal p85 inhibitory domain is modular and consists The p85 inhibitory domain may target molecules that regulate
of the LED and cSH2 motifs the enzymatic activity of p110. Alternatively, it may target mole-
A: Schematic diagrams of p85 constructs used in the experiments presented cules that function upstream of p110 to regulate its activation.
here. B: p85-CT and p85-DN inhibit the activation of the PI3K/Akt pathway
To distinguish between these possibilities, we examinedby H-Ras-G12V. The indicated constructs, in combination with a FLAG-cAkt
whether p85-CT inhibits the activity of p110-CAAX, a membraneconstruct, were transiently transfected into NIH3T3 cells. The Akt kinase activ-
ity was measured in anti-FLAG immunoprecipitates. Expression of FLAG-Akt bound, constitutively active p110 mutant (Klippel et al., 1996).
was determined by probing immunoblots of the immunoprecipitates with To this end, p85-CT or p85-DN constructs were transfected
a rabbit polyclonal anti-Akt antibody. Expression of H-Ras, p85-DN, and p85-
into NIH3T3 cells in combination with constitutively active p110CT was determined by probing immunoblots of total cell lysates with the
and FLAG-Akt. In vitro kinase assays of Akt immunoprecipitatedcorresponding antibodies. C: The PI3K inhibitory domain consists of the LED
and cSH2 motifs. NIH3T3 cells were transfected with the indicated constructs. from the transfected cells 48 hr later showed that the p85 inhibi-
Akt activity was measured by in vitro phosphorylation of H2B. Expression of tory domain blocks Akt activation by p110-CAAX (Figure 5A).
the HA-GFP fusion proteins and H-Ras-G12V was determined by probing Therefore, the p85 inhibitory domain targets molecules that di-immunoblots of total lysates with the anti-HA antibody. D: The cSH2 and
rectly regulate the activity of p110. A similar experiment compar-IKR/LED motifs alone have no inhibitory activity. NIH3T3 cells were trans-
fected with the indicated constructs. The phosphorylation of Akt at Thr308 ing the effects of p85-CT on membrane-targeted p110 and
was measured by immunoblotting. Expression of the transfected constructs p110, two type I PI3K molecules of which only the former binds
was determined by probing immunoblots with the corresponding anti- p85, showed that p85-CT inhibits only p110 (Figure 5B).
bodies.
PtdIns-3,4,5-P3 levels may be induced because of PI3K acti-
vation. Alternatively, they may be induced because of inactiva-
tion of PTEN, a tumor-suppressor gene that encodes a PtdIns-
3,4,5-P3 phosphatase (Cantley and Neel, 1999). The difference4A). Expression of the GFP fusion constructs in combination
between p110 and p110 suggests that the p85 inhibitorywith H-Ras-G12V in NIH3T3 cells showed that the IKR motif is
domain targets PI3K and not PTEN. To address this hypothesis,not required for the p85 inhibitory function (Figure 4C). Addi-
p85-CT or p85-DN constructs were transfected into the PTENtional deletions showed that the minimal inhibitory domain con-
null cell line, U87MG (Li et al., 1997), in combination with consti-tains both the LED and the carboxy-terminal SH2 domains.
tutively active H-Ras G12V and FLAG-Akt. The results showedDeletion of either domain abolished inhibitory function (Figure
that p85-CT blocks activation of the PI3K/Akt pathway by Ras,4D). Both the inhibitory protein LED/cSH2 and the noninhibiting
even in the absence of PTEN (Figure 5C). We conclude that thecSH2 were able to bind phosphotyrosine targets, suggesting
that they folded properly (data not shown). p85 inhibitory domain targets PI3K and not PTEN.
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Tyrosine kinase signals neutralize p85
inhibitory function
Rodriguez-Viciana et al. showed that forced expression of p85
fails to block Src-induced transformation of NIH3T3 cells (Rodri-
guez-Viciana et al., 1997). We, therefore, reasoned that p85
may not inhibit PI3K activation by Src. To test this hypothesis,
NIH3T3 cells were transfected with expression constructs of
p85-WT, H-Ras G12V, Src Y527F, and FLAG-Akt in the combi-
nation shown in Figure 6B. In vitro kinase assays of Akt carried
out 48 hr later, after overnight serum starvation, confirmed that
p85-WT blocks Akt activation by H-Ras but not by Src.
One possible explanation for the failure of p85 to block PI3K
activation by Src is that Src may neutralize the p85 inhibitory
domain. Therefore, when coexpressed with constitutively active
Src, wild-type p85 may become functionally equivalent to
p85onc. This model, if correct, would explain our previous
finding that Src and H-Ras synergize to activate the PI3K/Akt
pathway (Datta et al., 1996). To test this hypothesis, we wanted
to examine whether constitutively active Ras enhances Src plus
p85-induced PI3K/Akt activation in NIH3T3 cells. However, such
an experiment would be difficult to interpret, because Src is
known to activate Ras (Marais et al., 1995). To carry out this
experiment, therefore, we wanted to use a Src mutant that
retained the ability to neutralize the p85 inhibitory domain, but
no longer activated Ras. A G2A mutation that inactivates the
Src myristoylation signal (Figure 6A) renders Src defective in
Ras activation (Marais et al., 1995) without affecting its tyrosine
kinase activity (Kamps et al., 1986). Consistent with these data,
a Src G2A mutant (NM-Src) retained full tyrosine kinase activity
Figure 6. Ras-independent Src signals neutralize the p85 inhibitory domainbut did not activate the Ras/MAP kinase pathway in NIH3T3
A: Schematic diagram of the chicken Src tyrosine kinase and its mutantscells (Figure 6C). In addition, this mutant did not activate the
used in this report. B: p85-WT inhibits Akt activation by Ras but not by Src.PI3K/Akt pathway (Figure 6C). This mutant, similar to wild-type
NIH3T3 cells were transfected with the indicated constructs. Akt activity was
Src, was able to phosphorylate both endogenous and exoge- measured by in vitro phosphorylation of H2B. The expression of transfected
nous p85 (data not shown). proteins p85-WT, H-Ras, and Src-Y527F were monitored by probing immu-
noblots of total cell lysates with anti-HA antibody (H-Ras and p85-WT) orTo determine whether NM-Src induces Ras-dependent PI3K
anti-Src antibody (Src). C: Mutation of the Src myristoylation signal does notactivation, we examined whether, similar to its wild-type coun-
affect Src tyrosine kinase activity, but abolishes Src-induced activation of
terpart, NM-Src synergizes with Ras to activate the PI3K/Akt the Ras/ERK pathway and the PI3K/Akt pathway. The indicated Src con-
pathway. To this end, we coexpressed nonmyristoylated Src structs were transfected into NIH3T3 cells in combination with either HA-
ERK1 or FLAG-Akt. Src tyrosine kinase activity in vivo was determined by(NM-Src Y527F) or inactive Src (Src-K297M) with Ras-G12V in
probing total cell extracts with the anti-phosphotyrosine antibody, 4G10.NIH3T3 cells. The results (Figure 6D) showed that NM-Src-
HA-ERK1 phosphorylation at Thr202/Tyr204 was measured by probing HA
Y527F and Ras-G12V indeed synergizes to activate Akt in immunoprecipitates with an antibody that recognizes only the phosphory-
NIH3T3 cells. This synergy strongly suggests that NM-Src neu- lated ERK1. Phosphorylation of Akt at Thr308 was also measured by immu-
noblotting. Expression of transfected constructs was determined by probingtralizes the p85 inhibitory domain. To test this hypothesis di-
immunoblots of the cell lysates with the corresponding antibodies. D: Therectly, we transfected H-Ras-G12V and p85-WT in combination
nonmyristoylated Src mutant synergizes with H-Ras to activate the PI3K/Akt
with NM-Src and measured both the induction of PtdIns-3,4,5- pathway. The indicated constructs were transfected into NIH3T3 cells. Akt
P3 and the phosphorylation of Akt at Thr308 in the transfected activity was measured by in vitro phosphorylation of H2B. Expression of
transfected constructs was determined by probing immunoblots of totalcells (Figure 6E). Both measurements confirmed that p85-WT
cell lysates with the corresponding antibodies. E: The nonmyristoylated Srcdoes not inhibit PI3K activation by Ras signals in the presence
abolishes the inhibition of PtdIns-3,4,5-P3 production by p85. Constitutivelyof NM-Src. We conclude that Src transmits tyrosine-phosphory- active H-Ras-G12V was transfected in combination with p85-WT or nonmyris-
lation signals that neutralize the inhibitory domain of p85. toylated Src Y527F into NIH3T3 cells. Sixteen hours after transfection, 32P-
labeled PtdIns-3,4,5-P3 was measured as in Figure 1 (top gel). Akt phosphory-Many cytoplasmic tyrosine kinases and receptor tyrosine
lation at Thr308 was measured by immunoblotting in cell lysates from dupli-kinases are known to activate the PI3K/Akt pathway. We, there-
cate transfections. Expression of transfected constructs was determined byfore, tested some of these tyrosine kinases for their ability to probing immunoblots with the corresponding antibodies.
neutralize the p85 inhibitory domain. Using synergy with Ras
as the assay, we found that the Src catalytic domain (without
its SH2/SH3 domains), other cytoplasmic tyrosine kinases (Syk
and Abl but not p125FAK), and receptor tyrosine kinases (EGF, also showed that in addition to Ras and Rac1, small GTPases
PDGF, and IGF-1 receptors) all neutralize the inhibitory function R-Ras and CDC42, but not RhoA, cooperate with tyrosine ki-
of p85 (see Supplemental Figure S4 at http://www.cancercell. nases to activate the PI3K/Akt pathway (see Supplemental Fig-
ure S5).org/cgi/content/full/1/2/181/DC1). Using the same assay, we
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the arginine residue of the FLVR motif (Kuriyan and Cowburn,
1997). We, therefore, coexpressed the p85-CT R649L FLVR
mutant, which no longer binds tyrosine-phosphorylated mole-
cules (data not shown), in combination with Ras G12V into
NIH3T3 cells, and we examined whether the mutant continues
to inhibit PI3K/Akt activation by Ras. The result showed that
the R649L mutation abolished the inhibition of p85-CT (Figure
7B). We conclude that phosphotyrosine binding is required for
inhibition.
In addition to enabling phosphotyrosine binding, tyrosine
kinases, such as Abl and Lck, directly phosphorylate p85 cSH2
at tyrosine residue 688 (von Willebrand et al., 1998). To deter-
mine whether phosphorylation of this residue is involved in the
neutralization of the p85 inhibitory domain, we mutated it to a
phosphomimic aspartic acid (p85-CT Y688D). Coexpression of
p85-CT Y688D and Ras G12V in NIH3T3 cells showed that this
mutation abolished the inhibitory effect of p85-CT (Figure 7B).
On the other hand, p85-CT with a tyrosine to phenylalanine
mutation at this site (Y688F) continued to block Akt activation
by Ras (Figure 7C). Both p85-CT mutants were able to bind
tyrosine-phosphorylated molecules (data not shown), sug-
gesting that they fold properly. Consistent with these data, a
Y688D mutant of p85 continued to bind p110 but failed to inhibit
the basal activity of Akt in Cos7 cells (Cuevas et al., 2001).
We, therefore, conclude that both phosphotyrosine binding and
Y688 phosphorylation regulate p85 inhibitory function.
Since Rodriguez-Viciana et al. showed that full-length p85
blocks cell transformation by Ras (Rodriguez-Viciana et al.,
1997), we tested whether the inhibitory domain alone also blocks
transformation. To this end, we transfected p85-CT together
with activated Ras into NIH3T3 cells. Scoring for foci of transfor-
mation two weeks later revealed that the p85 inhibitory domain
is sufficient to block Ras-induced transformation (Figure 7D).
This blockage is specific because both the p85-CT (R649L) and
p85-cSH2 constructs failed to block. Blockage of transforma-
Figure 7. Mutations of the phosphotyrosine binding site and the Tyr688 phos-
tion, therefore, correlates perfectly with the blockage of PI3K/phorylation site of the cSH2 motif neutralize the inhibitory domain
Akt activation (Figures 4D and 7B).A: Schematic diagram of p85-CT. The diagram shows the phosphotyrosine
binding FLVR motif and the Y668 tyrosine-phosphorylation site. B: The R649L
and Y688D mutants of p85-CT do not inhibit activation of the PI3K/Akt path- Role of complimentary tyrosine kinase and small
way by Ras. The indicated constructs were transfected into NIH3T3 cells. Akt GTPase signals on PI3K activation in integrin
phosphorylation at Thr308 was determined by immunoblotting. Expression of
or growth factor-stimulated cellstransfected constructs was determined by probing immunoblots of total
Earlier studies by us and others (Clark et al., 1998; Djouder etcell lysates with the corresponding antibodies. C: The phosphorylation site
mutant Y688F continues to inhibit PI3K/Akt activation by Ras. Expression al., 2001; Franke et al., 1995; Genot et al., 2000; Klinghoffer et
constructs of p85-CT or p85-CT Y688F were transfected into NIH3T3 cells in al., 1996; Rodriguez-Viciana et al., 1994) had shown that small
combination with FLAG-Akt, as indicated. Akt phosphorylation at Thr308
GTPase signals are required for PI3K/Akt activation by growthand expression of the transfected constructs were measured by immu-
noblotting as in B. D: p85-CT blocks cell transformation by activated H-Ras. factors or integrin stimulation. To determine whether tyrosine
NIH3T3 (1.5  105 ) cells, cultured in100 mm petri dishes, were transfected kinase signals are also required, we examined whether a kinase-
with expression constructs of constitutively active H-Ras and wild-type or inactive, dominant-negative mutant of Src inhibits PI3K/Akt acti-mutant p85-CT in the indicated combinations. Three weeks after transfec-
vation induced by integrin stimulation. To address this question,tion, the cells were fixed with 70% methanol, and they were stained with
Giemsa (Chan et al., 1994). we took advantage of observations showing that in serum-
starved adherent cells, tyrosine kinase and small GTPase signals
are induced by matrix adhesion and that the small GTPase
signals are required for PI3K/Akt activation (Khwaja et al., 1997;cSH2 mutations abolish p85 inhibitory function
King et al., 1997). We, therefore, transfected mouse 3Y1 fibro-The preceding data suggest that Src and other tyrosine kinases
blasts with wild-type FLAG-Akt alone or in combination withtransmit signals that neutralize the p85 inhibitory domain. Since
kinase-inactive Src K279M. Following serum starvation, thethe inhibitory domain encompasses the p85 carboxy-terminal
cells were trypsinized and replated onto fibronectin-coatedSH2 motif (cSH2; Figure 7A), we asked whether its inhibitory
plates or control polylysine-coated plates for 30 min. The resultsfunction depends on phosphotyrosine binding. Binding of all
SH2 domains to phosphotyrosine can be abolished by mutating showed that Akt activation in the fibronectin-coated plates is
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inhibited by Src K279M (Figure 8A). These results support the
hypothesis that Src signals are required, in combination with
small GTPase signals, for PI3K/Akt activation by integrin stimu-
lation.
To further explore the physiological role of complimentary
signals transduced by tyrosine kinases and small GTPases, we
employed suspension cultures of immortalized keratinocytes
(HaCaT cells; Frisch and Francis, 1994). Cell culture under con-
ditions of forced suspension precludes integrin engagement
and signaling and can be performed in defined media free of
exogenous growth factors. In the absence of integrin-generated
signals, these cells fail to activate the PI3K/Akt pathway and
undergo apoptosis (anoikis). Previous studies, using suspension
cultures of MDCK cells, suggested that activated Ras alone
activates the PI3K/Akt pathway and rescues the cells from ano-
ikis (Khwaja et al., 1997). These findings suggested that, in this
experimental setting, Ras alone was sufficient to activate PI3K/
Akt and seemingly argued against an obligatory role of tyrosine
kinases in this process. However, all these experiments were
performed in serum-containing media which could generate
tyrosine kinase signals that synergize with Ras. To avoid this
problem, our experiments were carried out in serum-free defined
media. The results (Figure 8B) showed that constitutively active
H-Ras G12V activates the PI3K/Akt pathway and rescues cells
from anoikis only in suspension cultures supplemented with
epidermal growth factor (EGF). Ras G12V-alone in the absence
of EGF and EGF-alone in the absence of H-Ras G12V were
inefficient in PI3K/Akt activation and failed to rescue the cells
from anoikis. These results support the hypothesis that PI3K/Akt
activation and inhibition of anoikis depend on the combination of
tyrosine kinase and small GTPase signals.
Discussion
Based on the preceding data, we suggest a regulatory mecha-
nism to explain how cytoplasmic tyrosine kinases and small
GTPases regulate PtdIns-3,4,5-P3 production by type IA PI3K.
This model also explains how the carboxy-terminally truncated Figure 8. Complimentary roles of tyrosine kinase and small GTPase signals
p85 functions as an oncogene. According to this model (Figure induced by integrin or growth factor stimulation, in PI3K/Akt activation and
cell survival8C), type IA PI3K activity is under the dual control of a p85
inhibitory domain, which is regulated by binding to tyrosine- A: Inhibition of fibronectin-stimulated Akt activity by kinase-inactive Src.
Serum-starved Mouse 3Y1 fibroblasts, cotransfected with FLAG-Akt and ki-phosphorylated molecules and by tyrosine phosphorylation, and
nase-inactive Src-K297M or vector, were trypsinized and replated in fibro-a GTPase-responsive domain (GRD). Because of the inhibitory
nectin or polylysine-coated plates as indicated. Akt kinase activity in celldomain, PI3K either does not respond or responds poorly to lysates harvested 30 min later was measured by in vitro phosphorylation of
signals from small GTPases such as Ras or Rac1. Removal of H2B. B: Activated Ras and EGF cooperate to support long-term cell survival
(10 days) and PI3K/Akt activation in HaCaT keratinocytes in suspensionthe inhibitory domain, as in the case of the p85 oncogene, or
cultures. HaCaT cells or HaCaT cells stably expressing activated H-Ras G12Vneutralization of its inhibitory function by tyrosine phosphoryla-
were cultured on 0.9% agarose in MCDB base medium. EGF was used attion allows small GTPases to activate PI3K through the GRD.
2 nM concentration in the indicated cultures. Cell aliquots were removed
The inhibitory domain and the GRD together form a molecular after 6 hr in suspension for immunoblot analysis. Cell viability was examined
switch that regulates the enzyme. after 10 days in suspension as described (Jost et al., 2001). C: A model of PI3K
activation by tyrosine kinase signals and small GTPase signals. According toThese data raise the question of the molecular mechanism
this model, p85 binds, via its cSH2 motif, tyrosine-phosphorylated proteinsthrough which tyrosine kinases and small GTPases regulate the
and undergoes phosphorylation at Y688. Phosphorylation at this site func-
switch. The inhibitory domain, which consists of the cSH2 and tionally inactivates the p85 inhibitory domain. Neutralization of the inhibitory
the adjacent LED motifs, was inactivated by a mutation (R649L) domain renders p85 responsive to PI3K activation signals that are trans-
duced by small GTPases.in the FLVR region of cSH2. Since this mutation eliminates
binding to phosphotyrosine, we conclude that the inhibitory
function of this domain depends on its binding to tyrosine-
phosphorylated molecules. One potential explanation for this data because the cSH2 domain alone, which should also bind
result is that the overexpressed p85 inhibitory domain competes these sites, has no inhibitory activity. Therefore, the LED motif
with endogenous p85 for binding to tyrosine-phosphorylated is an indispensable part of the inhibitory domain.
The role of the LED motif is not clear to date. One potentialmolecules. However, this hypothesis cannot fully explain our
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clue regarding its function is that the inhibitory domain is modu- The mechanism of PI3K activation via the synergistic action
of two different classes of signaling molecules defines a signal-lar and functions in trans, despite the fact that it does not bind
p110. This suggests that the LED motif may regulate the confor- ing paradigm for PtdIns-3,4,5-P3 regulation. According to this
paradigm, a given molecule may be the target of two simultane-mation of p85, perhaps through electrostatic and/or hydropho-
bic interactions with the IKR motif. Changes in the conformation ously activated, converging pathways, one of which molecularly
modifies the target so that it can be recognized by the other.of p85 may affect the activity of p110. One possible mechanism
by which conformational changes of p85 regulate the activity Synergism between a variety of tyrosine kinases and small
GTPases suggests that external signals may use different com-of the catalytic subunit is that such changes may directly affect
the conformation of the p85 bound p110. Alternatively, confor- binations of these two classes of molecules to activate PI3K.
In agreement with this, a kinase-inactive mutant of Src (Figuremational changes of p85 may affect the ability of p110 to dimer-
ize. This hypothesis is supported by earlier findings showing 8A) and a dominant-negative mutant of CDC42 (Clark et al.,
1998) inhibit PI3K activation by integrin stimulation, and a domi-that PI3K dimerizes in vitro and that dimerization is promoted
by binding to tyrosine-phosphorylated peptides (Layton et al., nant-negative mutant of H-Ras partially inhibits PI3K activation
by PDGF and NGF (Franke et al., 1995; Klinghoffer et al., 1996;1998). The interaction between the IKR and LED motifs was
suggested by the abundance of conserved hydrophobic and Rodriguez-Viciana et al., 1994). Moreover, in hematopoietic
cells, PtdIns-3,4,5-P3 induction by the IgE receptor, FcRI, orpositively charged amino acids in the IKR motif and hydrophobic
and negatively charged amino acids in the LED motif. Support- by the T cell receptor requires Rac1 signals (Djouder et al.,
2001; Genot et al., 2000). Data presented in this report showeding the hypothesis that such interactions indeed take place and
that they are functionally important are recent findings showing that the p85 inhibitory domain blocks Ras-induced transforma-
tion of NIH3T3 cells. In addition, they showed that both constitu-that mutations designed to disrupt the interaction between the
IKR and LED motifs abolish the function of the p85 inhibitory tively active Ras and EGF are required for Akt activation and
protection from apoptosis. These results strongly support thedomain (data not shown). The inhibitory function of the LED motif
could be affected by conformational changes of p85 induced by physiological relevance of the model of PI3K activation de-
scribed in this report.tyrosine phosphorylation. Cuevas et al. (2001), indeed, pro-
posed that phosphorylation of Y688 promotes intramolecular In summary, data in this report show that p85 contains a
molecular switch that regulates PI3K in response to signalsinteractions between nSH2 and cSH2. Such interactions may
induce conformational changes that affect the inhibitory activity transduced by tyrosine kinases and small GTPases. Given the
significance of the PI3K pathway in oncogenesis, this molecularof the LED motif.
The preceding data suggest a model according to which PI3K switch defines an important target for future chemotherapeutic
drugs.is inactive in quiescent cells, in part because the p85 inhibitory
domains binds tyrosine-phosphorylated molecules with inhibitory
Experimental proceduresproperties. Following signals that activate tyrosine kinases, p85
undergoes phosphorylation in a number of sites, including tyro-
Cell culture, transfection, and plasmids
sine 668. Since a Y668F mutation did not affect the function of NIH3T3 fibroblasts were cultured in Dulbecco’s Modified Eagle’s Essential
the inhibitory domain while a phosphomimetic Y668D mutation Medium (DMEM) supplemented with 10% calf serum and antibiotics. Immor-
completely abolished its activity, we conclude that phosphoryla- talized, nontumorigenic human keratinocytes (HaCaT cells) (Boukamp et al.,
1988) and their tumorigenic variant expressing the activated H-Ras G12Vtion of this site is sufficient to neutralize this domain. Neutraliza-
(Boukamp et al., 1990) were obtained from N. Fusenig. Cells were transfectedtion of p85 by phosphorylation may be mediated by one of
using LipofectAMINE (GIBCO-BRL) or Fugene-6 (Roche) according to theseveral tyrosine kinases, including Src, Lck, Abl, EGF-R,
manufacturer’s protocols. All constructs, except where noted, were gener-
PDGF-R, and IGF-R, which are known to phosphorylate this ated in the mammalian expression vector, CMV5. The Src myristoylation
molecule (von Willebrand et al., 1998; Wymann and Pirola, 1998) signal (MGSSKSKPK), an extended Hemagglutinin epitope (HA) (MASSY-
and to cooperate with small GTPases in PI3K activation (see PYDVPDYASLGGPSRST), and a FLAG-epitope tag (MDYKDDDDK) were
fused at the amino terminus of the indicated constructs. Green fluorescenceSupplemental Figure S5 at http://www.cancercell.org/cgi/
protein (GFP) in pFred143(KH1035) was a gift from G. Pavlakis, p110--content/full/1/2/181/DC1). This raises the question of the mech-
CAAX in pMT2 was a gift from K. Kotani, and p110--CAAX in pCDNA3 wasanism through which phosphorylation of tyrosine 668 neutral-
a gift from M. Wymann. Additional details are available in the Supplementalizes the inhibitory domain. One possibility is that phosphoryla-
Data at http://www.cancercell.org/cgi/content/full/1/2/181/DC1.
tion alters the conformation of the protein and makes the GRD
domain accessible to small GTPase signals. This conformational In vivo labeling of PtdIns-3,4,5-P3
PtdIns-3,4,5-P3 was measured in lipid extracts of 32P-labeled NIH3T3 cellschange may be the direct outcome of phosphorylation. Alterna-
by thin-layer chromatography (Maehama and Dixon, 1998). Approximatelytively, phosphorylation of tyrosine 668 may selectively alter the
2  105 NIH3T3 cells plated into 35 mm Petri dishes were transfected withspectrum of proteins that bind the cSH2 motif. Previous studies
constitutively active H-Ras G12V, p85-WT, and p85onc constructs in CMV5by von Willebrand et al. (1998) indeed showed that phosphoryla-
using Fugene 6 (Roche). Sixteen hours later, the transfected cells were
tion at this site in pervanadate-treated Jurkat cells selectively serum-starved for 5 hr and following this, they were labeled for 1.5 hr with
alters the spectrum of p85 binding proteins. Please note that 100 uci/ml 32P-orthophosphate in a phosphate-free buffer (10 mM Hepes
selective shifts in the spectrum of proteins binding the PI3K [pH 7.5], 136 mM NaCl, 4.9 mM KCl, and 5.5 mM glucose). For wortmannin
treatment, 200 nM wortmannin was added to cells 45 min prior to cellcomplex could potentially also occur because of oligomerization
extraction. Further details are provided in the Supplemental Data at http://induced by binding of p85 to tyrosine-phosphorylated proteins
www.cancercell.org/cgi/content/full/1/2/181/DC1.(Layton et al., 1998). The conformational change that neutralizes
the inhibitory domains may therefore be caused by the dissocia- Akt kinase assay
tion of inhibitory molecules from the PI3K complex and/or by Akt/PKB kinase activation was determined either by measuring the phos-
phorylation of Akt at Thr308 using an antibody from Cell Signaling Technol-the association of the complex with activating molecules.
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activated by phosphopeptides that bind to the SH2 domains of the 85-kDaogy or by measuring the kinase activity of immunoprecipitated FLAG-tagged
subunit. J. Biol. Chem. 268, 9478–9483.wild-type Akt (Bellacosa et al., 1998; Franke et al., 1995). Detailed protocols
for the Akt kinase assay are available in the Supplemental Data at http:// Chan, A.M., Miki, T., Meyers, K.A., and Aaronson, S.A. (1994). A human
www.cancercell.org/cgi/content/full/1/2/181/DC1. Specific Akt kinase activ- oncogene of the RAS superfamily unmasked by expression cDNA cloning.
ity was determined by Phosphorimager quantitation of the 32P-phosphory- Proc. Natl. Acad. Sci. USA 91, 7558–7562.
lated Akt substrate Histone 2B and by quantification of Akt in anti-Akt immu-
Chan, T.O., Rittenhouse, S.E., and Tsichlis, P.N. (1999). AKT/PKB and othernoprecipitates using a laser densitometry scanner (Molecular Dynamics).
D3 phosphoinositide-regulated kinases: kinase activation by phosphoinosi-
tide-dependent phosphorylation. Annu. Rev. Biochem. 68, 965–1015.Immunoblotting
Total cell lysates and protein immunoprecipitates were subjected to SDS- Clark, E.A., King, W.G., Brugge, J.S., Symons, M., and Hynes, R.O. (1998).
PAGE. The SDS-PAGE-resolved proteins were transferred onto PVDF mem- Integrin-mediated signals regulated by members of the rho family of
branes (Immobilon P, Millipore) and the resulting immunoblots were probed GTPases. J. Cell Biol. 142, 573–586.
with the appropriate antibodies. Binding of antibodies to membrane-immobi-
Cuevas, B.D., Lu, Y., Mao, M., Zhang, J., LaPushin, R., Siminovitch, K., andlized proteins was visualized by enhanced chemiluminescence (ECL, Amer-
Mills, G.B. (2001). Tyrosine phosphorylation of p85 relieves its inhibitorysham) following the manufacturer’s protocol.
activity on phosphatidylinositol 3-kinase. J. Biol. Chem. 276, 27455–27461.The origin of the antibodies we used is described in the Supplemental
Data at http://www.cancercell.org/cgi/content/full/1/2/181/DC1. Datta, K., Bellacosa, A., Chan, T.O., and Tsichlis, P.N. (1996). Akt is a direct
target of the phosphatidylinositol 3-kinase. Activation by growth factors,
Transformation assay and suspension survival assay v-src and v-Ha-ras, in Sf9 and mammalian cells. J. Biol. Chem. 271, 30835–
Transformation assays in NIH3T3 cells were performed as previously described 30839.
(Chan et al., 1994; Wigler et al., 1977). Suspension survival assays were
Dhand, R., Hara, K., Hiles, I., Bax, B., Gout, I., Panayotou, G., Fry, M.J.,performed as previously described (Jost et al., 2001). Brief description of
Yonezawa, K., Kasuga, M., and Waterfield, M.D. (1994). PI 3-kinase: struc-these assays is provided in the Supplemental Data at http://www.cancercell.
tural and functional analysis of intersubunit interactions. EMBO J. 13, 511–org/cgi/content/full/1/2/181/DC1.
521.
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